Trabectedin combined with low-dose cyclophosphamide modulates macrophage polarization in the sarcoma microenvironment, reducing M2 macrophages and increasing CD8+ T cells that correlated with improved prognosis (81, 82). The gene discussed is CD8A; the disease is sarcoma.